Startthread zu THOMAS PHARMAC - 500 Beiträge pro Seite
eröffnet am 19.09.09 20:05:44 von
neuester Beitrag 15.02.11 20:50:05 von
neuester Beitrag 15.02.11 20:50:05 von
Beiträge: 38
ID: 1.153.133
ID: 1.153.133
Aufrufe heute: 0
Gesamt: 4.219
Gesamt: 4.219
Aktive User: 0
ISIN: US88445L1017 · WKN: A0M8Q8
0,0001
USD
0,00 %
0,0000 USD
Letzter Kurs 05.11.15 Nasdaq OTC
Neuigkeiten
Werte aus der Branche Pharmaindustrie
Wertpapier | Kurs | Perf. % |
---|---|---|
1,2000 | +471,16 | |
13,110 | +38,44 | |
1,1514 | +30,84 | |
0,5150 | +30,05 | |
1,4400 | +24,14 |
Wertpapier | Kurs | Perf. % |
---|---|---|
6,9450 | -19,80 | |
2,4600 | -21,66 | |
36,70 | -22,87 | |
10,480 | -24,82 | |
2,7280 | -29,14 |
Eröffnung Startthread zu THOMAS PHARMAC.
Jetzt kann hier gepostet werden.
Jetzt kann hier gepostet werden.
Antwort auf Beitrag Nr.: 38.016.222 von i2fan am 19.09.09 20:05:44Jetzt kann hier gepostet werden.
Danke!
Na dann will ich mal:
Danke!
Na dann will ich mal:
Antwort auf Beitrag Nr.: 38.016.222 von i2fan am 19.09.09 20:05:44Jetzt kann hier gepostet werden.
ich will dann auch mal:
ich will dann auch mal:
Antwort auf Beitrag Nr.: 38.016.512 von suuperbua am 19.09.09 21:43:06na jungs . ihr habts ja gut drauf..
schätze bald gehts hier los.
schneewittchen wurde wachgeküsst.
schätze bald gehts hier los.
schneewittchen wurde wachgeküsst.
Antwort auf Beitrag Nr.: 38.016.258 von Datteljongleur am 19.09.09 20:12:44na. kommt doch wieder bewegung rein
Ist noch jemand von Euch investiert ?
Antwort auf Beitrag Nr.: 38.690.296 von dertagistnah am 08.01.10 09:25:00yep.
kommt wieder bewegung in das tote pferd
kommt wieder bewegung in das tote pferd
Antwort auf Beitrag Nr.: 38.928.737 von upanddown66 am 11.02.10 19:01:54und jetzt richtig (bewegung)!!
Antwort auf Beitrag Nr.: 38.968.042 von upanddown66 am 18.02.10 17:01:16Umsatz: 1328,00 USD!!
Sparschwein geschlachtet und all in?
Sparschwein geschlachtet und all in?
Antwort auf Beitrag Nr.: 38.968.080 von Datteljongleur am 18.02.10 17:04:36mach mal die augen auf , kamerad!!
hier der grund:
All Press Releases for February 18, 2010 Subscribe to this News Feed
Thomas Pharmaceuticals, Ltd to Merge with Global Medical Equipment of AZ
Global Medical is involved with launching a series of patented products servicing home and institutional health care, specialty medical facilities, acute care facilities, and elder care
hier der grund:
All Press Releases for February 18, 2010 Subscribe to this News Feed
Thomas Pharmaceuticals, Ltd to Merge with Global Medical Equipment of AZ
Global Medical is involved with launching a series of patented products servicing home and institutional health care, specialty medical facilities, acute care facilities, and elder care
plus 136% vol.147,282,681
Antwort auf Beitrag Nr.: 38.976.796 von oski am 19.02.10 19:17:29rüüüüüüchtig !!
erzähl das mal dem "dattel-heinz" der hier gestern gross rumpupste.
erzähl das mal dem "dattel-heinz" der hier gestern gross rumpupste.
Wow gerade waren es 900% und das in 5 Tagen. Leider habe ich nur 20.000 Stück. Damals bekommen beim Kauf von Ivoice, wohl als Dividende. Dachte nicht, dass die irgendwann mal was wert sein könnten.
Gruß tomcat17
Gruß tomcat17
Antwort auf Beitrag Nr.: 38.986.260 von tomcat17 am 22.02.10 15:56:04ist es ein Fake?????
habe über 1 Mio Dinger rumliegen - im nebendepot und habe zufällig mal draugeschat.
gibt es irgendetwas neues?
habe nur dies gefunden:
http://www.earthtimes.org/articles/show/cybl-tphm-and-wdrp-a…
habe über 1 Mio Dinger rumliegen - im nebendepot und habe zufällig mal draugeschat.
gibt es irgendetwas neues?
habe nur dies gefunden:
http://www.earthtimes.org/articles/show/cybl-tphm-and-wdrp-a…
Antwort auf Beitrag Nr.: 38.986.487 von hardy14 am 22.02.10 16:17:47Sind noch die Nachwirkungen von Freitag Bei dem Wort Merger drehen drüben manche am Rad , kann wohl noch ein Paar Tage so weiter gehen .
Viel Glück
Papschy
Viel Glück
Papschy
0.004 plus 90% 94,791,314
Antwort auf Beitrag Nr.: 38.986.602 von papschy am 22.02.10 16:26:20Wahnsinn, wenn man es abgelegt hat in einem Nebendepot, weil man dachte, dies ist wertlos. Was macht man nun....immer die gleiche Frage, tag täglich, minütlich .....
jeden Tag 0,001 höher (seit 3 Tagen bisher)...bin gespannt.
denke aber, daß es heute etwas zur Konsolidierung kommt,
evtl. sogar leicht im Minus endet.
hoffe natürlich nicht, aber wir werden sehen.
Good Luck
denke aber, daß es heute etwas zur Konsolidierung kommt,
evtl. sogar leicht im Minus endet.
hoffe natürlich nicht, aber wir werden sehen.
Good Luck
Antwort auf Beitrag Nr.: 38.992.809 von hardy14 am 23.02.10 13:05:34die scheinen wieder angeblasen zu werden....
Antwort auf Beitrag Nr.: 39.574.668 von upanddown66 am 24.05.10 16:41:57NEWS!
Thomas Pharmaceuticals, Ltd. (TPHM) - Financial And Strategic Analysis Review - New Company Profile Published
Newly released report, Thomas Pharmaceuticals, Ltd. (TPHM) - Financial and Strategic Analysis Review, provides detailed company analysisPublished on June 10, 2010
by Press Office
(Companiesandmarkets.com and OfficialWire)
LONDON, ENGLAND
Thomas Pharmaceuticals, Ltd. (TPHM) - Financial and Strategic Analysis Review
Thomas Pharmaceuticals, Ltd. focuses on relaunching products with proven effectiveness and usefulness such as: antacids, by improving their formulation, packaging, marketing and advertising to match the expectations of new generation consumers. In January 2006, the company launched its first product, Acid+All, a calcium-enriched, sugar free, anti-gas antacid tablet. But, following its lack of proper financing arrangements, the company realized steady decline in its product sales. As a result, retailers decided not to carry the Acid+All product any longer. Further, the company's newly formed wholly owned subsidiary, Small Cap Advisors, Inc.
Thomas Pharmaceuticals, Ltd. Key Recent Developments
Feb 19, 2010: Thomas Pharmaceuticals To Merge With Global Medical Equipment
This comprehensive SWOT profile of Thomas Pharmaceuticals, Ltd. provides you an in-depth strategic analysis of the company's businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
This company report forms part of the 'Profile on Demand' service, covering over 50,000 of the world's leading companies. Once purchased, the highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Thomas Pharmaceuticals, Ltd., including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days (excluding weekends).
The profile contains critical company information including*,
- Business description - A detailed description of the company's operations and business divisions.
- Corporate strategy - Analyst's summarization of the company's business strategy.
- SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives' employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities - A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note*: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include,
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Thomas Pharmaceuticals, Ltd. (TPHM) - Financial and Strategic Analysis Review: http://www.companiesandmarkets.com/r.ashx?id=5N71J4NS1295999…
Contact
CompaniesandMarkets.com
Mike King
info@companiesandmarkets.com
Tel: +44 (0) 2030868600
Posted 6/10/2010 7:04 AM
Thomas Pharmaceuticals, Ltd. (TPHM) - Financial And Strategic Analysis Review - New Company Profile Published
Newly released report, Thomas Pharmaceuticals, Ltd. (TPHM) - Financial and Strategic Analysis Review, provides detailed company analysisPublished on June 10, 2010
by Press Office
(Companiesandmarkets.com and OfficialWire)
LONDON, ENGLAND
Thomas Pharmaceuticals, Ltd. (TPHM) - Financial and Strategic Analysis Review
Thomas Pharmaceuticals, Ltd. focuses on relaunching products with proven effectiveness and usefulness such as: antacids, by improving their formulation, packaging, marketing and advertising to match the expectations of new generation consumers. In January 2006, the company launched its first product, Acid+All, a calcium-enriched, sugar free, anti-gas antacid tablet. But, following its lack of proper financing arrangements, the company realized steady decline in its product sales. As a result, retailers decided not to carry the Acid+All product any longer. Further, the company's newly formed wholly owned subsidiary, Small Cap Advisors, Inc.
Thomas Pharmaceuticals, Ltd. Key Recent Developments
Feb 19, 2010: Thomas Pharmaceuticals To Merge With Global Medical Equipment
This comprehensive SWOT profile of Thomas Pharmaceuticals, Ltd. provides you an in-depth strategic analysis of the company's businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
This company report forms part of the 'Profile on Demand' service, covering over 50,000 of the world's leading companies. Once purchased, the highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Thomas Pharmaceuticals, Ltd., including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days (excluding weekends).
The profile contains critical company information including*,
- Business description - A detailed description of the company's operations and business divisions.
- Corporate strategy - Analyst's summarization of the company's business strategy.
- SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives' employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities - A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note*: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include,
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Thomas Pharmaceuticals, Ltd. (TPHM) - Financial and Strategic Analysis Review: http://www.companiesandmarkets.com/r.ashx?id=5N71J4NS1295999…
Contact
CompaniesandMarkets.com
Mike King
info@companiesandmarkets.com
Tel: +44 (0) 2030868600
Posted 6/10/2010 7:04 AM
Antwort auf Beitrag Nr.: 39.703.149 von gled77 am 18.06.10 10:01:35hi....
genau das wollte ich auch gerade reinstellen.
sieht doch gut aus.
genau das wollte ich auch gerade reinstellen.
sieht doch gut aus.
Antwort auf Beitrag Nr.: 39.703.149 von gled77 am 18.06.10 10:01:35kommt immerhin wieder volumen rein.
Man könnte sich wieder günstig eindecken......1 -2 in Usa !!! Der nächste Hype kommt bestimmt. Alles eine Frage der Zeit !
Antwort auf Beitrag Nr.: 40.312.612 von dertagistnah am 13.10.10 13:50:21richtig.
und die zeit naht.
es kommt bewegung rein.
und die zeit naht.
es kommt bewegung rein.
Jep !
Hast Du auch zugeschlagen ? Bin seit 1-2 dabei ! ( Mittelkurs ,00016 )
Sieht doch schonmal sehr gut aus. Aber zum Jahresbeginn 2010 gab es eine Rally bis ,0045 !!!
Da will ich wieder hin.....warte auch gerne noch bis Jahresanfang ;-)
Keine Kaufempfehlung, aber Träume darf man ja haben ......
Hast Du auch zugeschlagen ? Bin seit 1-2 dabei ! ( Mittelkurs ,00016 )
Sieht doch schonmal sehr gut aus. Aber zum Jahresbeginn 2010 gab es eine Rally bis ,0045 !!!
Da will ich wieder hin.....warte auch gerne noch bis Jahresanfang ;-)
Keine Kaufempfehlung, aber Träume darf man ja haben ......
wieso auch nicht o/s niedrig merger news könnten bald anstehen
Antwort auf Beitrag Nr.: 40.496.468 von oski am 10.11.10 21:00:29Richtig ! Könnte sein. Und die Stückzahl in diesem Wert ist relativ ( zu vergleichbaren Werten ) gering !
Und diese Aktie hat kaum einer auf der Watchlist bzw. im Depot !
Antwort auf Beitrag Nr.: 40.496.310 von dertagistnah am 10.11.10 20:39:54jep. kaum beachtet umso grösser wird der nächste sprung.
kann schnell auf 0.002 0.003 gehen m.e.
kann schnell auf 0.002 0.003 gehen m.e.
Antwort auf Beitrag Nr.: 40.496.533 von dertagistnah am 10.11.10 21:07:15stimmt. aber bald.
geht wieder los.....
geht wieder los.....
wieso auch nicht,warte noch auf den merger
Antwort auf Beitrag Nr.: 40.916.231 von oski am 24.01.11 19:59:11bald gehts los.
etwas volumen und ruckzuck > .001
etwas volumen und ruckzuck > .001
Antwort auf Beitrag Nr.: 40.916.231 von oski am 24.01.11 19:59:11jetzt haben wir schon die 6 im ask.
schleicht sich hoch.
schleicht sich hoch.
seit langem mal wieder ein bid mit 0.0004
Antwort auf Beitrag Nr.: 40.916.231 von oski am 24.01.11 19:59:11so. die 3 ist aussem ask raus.
auf ihub meint man:
THOMAS PHARMACEUTICALS LTD Ticker--TPHM
Thomas Parmaceuticals is currently seeking a business partner, stock is a shell at this time.
auf ihub meint man:
THOMAS PHARMACEUTICALS LTD Ticker--TPHM
Thomas Parmaceuticals is currently seeking a business partner, stock is a shell at this time.
wow danke für die info, lets go up
Antwort auf Beitrag Nr.: 41.027.423 von oski am 11.02.11 19:40:38wurden gerade 1 mio für 5 drüben umgesetzt.
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
Wertpapier | Perf. % |
---|---|
-29,76 | |
-2,21 | |
-1,60 | |
+2,22 | |
-8,99 | |
+5,41 | |
0,00 | |
-2,40 | |
-47,90 | |
-3,52 |
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
206 | ||
75 | ||
71 | ||
63 | ||
51 | ||
44 | ||
38 | ||
36 | ||
36 | ||
24 |